GlassScriptPhysician profile
Luke Bor-Ren Chen
NPI 1700889243
$7,951.29
in general payments reported to CMS, 2019-2025
35 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $240 · 2021: $274 · 2022: $937 · 2023: $1,870 · 2024: $2,261 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,871.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,645.89 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $882.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $602.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.55 | 2019-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Glaxosmithkline, LLC. | $548.19 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $506.95 | 2019-2025 | |
| Exact Sciences Corporation | $506.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $405.60 | 2022-2025 | |
| Amgen INC. | $358.40 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $305.15 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $302.94 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Phathom Pharmaceuticals, INC. | $150.82 | 2023-2025 | Voquezna |
| Abbvie INC. | $149.89 | 2023-2025 | Vraylar, Viberzi, Linzess |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.37 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $104.13 | 2022-2024 | Glassia, Trintellix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $94.03 | 2022-2025 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $86.66 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $68.08 | 2022-2024 | Quviviq |
| Insulet Corporation | $59.36 | 2024-2025 | Omnipod |
| Mannkind Corporation | $56.44 | 2022 | |
| Inogen, INC. | $54.03 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Astellas Pharma US INC | $53.33 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $50.58 | 2022 | |
| Amarin Pharma, INC. | $30.58 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.53 | 2023 | Xifaxan, Trulance |
| Abbott Laboratories | $23.42 | 2022 | |
| Sanofi Pasteur INC. | $20.58 | 2022 | |
| Alkermes, INC. | $19.69 | 2024 | Aristada, Lybalvi |
| Inspire Medical Systems, INC. | $19.52 | 2025 | Inspire |
| Genentech USA, INC. | $19.10 | 2019 | |
| Indivior INC. | $17.26 | 2024 | Sublocade |
| Corcept Therapeutics | $16.81 | 2023 | Korlym |
| Collegium Pharmaceutical, INC. | $15.83 | 2022 | |
| Shield Therapeutics INC | $15.54 | 2024 | |
| Almatica Pharma LLC | $15.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.